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Abstract
Background: The bleeding phenotype of von Willebrand disease (VWD) varies highly 
between patients and can only partly be explained by von Willebrand factor (VWF) 
parameters. By cleaving large VWF multimers into smaller, less active multimers, 
ADAMTS-13 is an important regulator of VWF activity. However, it is unknown what 
the role of ADAMTS-13 is in individuals with VWD.
Objectives: We therefore studied how ADAMTS-13 activity is associated with the 
laboratory and bleeding phenotype in individuals with VWD.
Methods: We measured ADAMTS-13 activity using the fluorescence resonance en-
ergy transfer substrate VWF 73 assay in 638 individuals with VWD in the nationwide 
cross-sectional Willebrand in the Netherlands study and in 36 healthy controls. The 
bleeding phenotype was assessed using the Tosetto bleeding score.
Results: ADAMTS-13 activity was similar in individuals with VWD (109% ± 20.6%) 
and controls (110% ± 19.7%). ADAMTS-13 activity was higher in individuals with 
VWD with type 3 than those with type 1 (mean difference, 11.8%; 95% confi-
dence interval [CI], 2.9%-20.8%) or type 2 (mean difference, 16.1%; 95% CI, 7.1%-
25.1%). ADAMTS-13 activity was not associated with the Tosetto bleeding score 
(0.1 Tosetto bleeding score increase per 10% ADAMTS-13 increase, 95% CI, −0.2 to 
0.3). Furthermore, ADAMTS-13 activity did not differ between individuals with and 
without a bleeding event during the year preceding blood sampling (mean difference, 
1.4%; 95% CI, −2.1% to 4.9%).
Conclusion: ADAMTS-13 activity was highest in individuals with type 3 VWD, but 
it had only minor associations with VWF parameters. ADAMTS-13 activity does not 
influence the bleeding phenotype in individuals with VWD.
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Essentials
• Mild reduction of ADAMTS-13 levels are associated with thrombosis, and may be associated with lower risk of bleeding.
• We studied how ADAMTS-13 is associated with the laboratory and bleeding phenotype in individuals with von Willebrand disease (VWD).
• ADAMTS-13 activity was associated with VWD type, but not with von Willebrand factor antigen or activity.
• ADAMTS-13 activity was not associated with the bleeding phenotype of individuals with VWD.
1  | INTRODUCTION
Von Willebrand factor (VWF) plays an important role in both pri-
mary and secondary hemostasis. By mediating platelet adhesion and 
aggregation at sites of vessel damage, VWF is essential in the for-
mation of the platelet plug. Upon stimulation, endothelial cells se-
crete VWF as ultra-large multimers. These ultra-large multimers are 
highly procoagulant and, to prevent spontaneous thrombosis, must 
be cleaved into smaller, less procoagulant multimers. This cleavage is 
mediated by ADAMTS-13.
The importance of ADAMTS-13 in the regulation of VWF activ-
ity becomes evident in patients with thrombotic thrombocytopenic 
purpura, a potentially fatal disease in which a severe deficiency of 
ADAMTS-13 leads to uncontrolled and diffuse formation of mi-
crothrombi and microangiopathy.1 Recently, large prospective 
population-based cohort studies have linked mild reductions in 
ADAMTS-13 to arterial thrombosis. In these studies, elderly indi-
viduals in the lowest quartile of ADAMTS-13 activity (≤ 81%) had a 
49% higher risk of ischemic stroke and a 42% higher risk of coronary 
heart disease than individuals in the highest quartile of ADAMTS-13 
activity during a 10-year follow-up period.2,3 This increased risk was 
independent of VWF levels.
A deficiency or dysfunction of VWF causes the bleeding disorder 
von Willebrand disease (VWD).4 In VWD type 2A, specific mutations 
in the VWF gene can lead to an increased susceptibility of VWF to 
cleavage by ADAMTS-13, causing absence of high-molecular-weight 
multimers and consequently impaired VWF function.
The bleeding phenotype of VWD is highly variable and can only 
partly be explained by differences in VWF level.5 One promising 
candidate that may explain part of this variation is ADAMTS-13, but 
no studies have been performed yet on the association between 
ADAMTS-13 and bleeding. Only a few studies have been performed 
on ADAMTS-13 activity in VWD. In these studies, individuals with 
type 3 VWD had higher ADAMTS-13 activity than healthy controls, 
and ADAMTS-13 activity decreased following administration of des-
mopressin or VWF concentrate.6,7
Because ADAMTS-13 is an important regulator of VWF activity, 
we hypothesized that variations in ADAMTS-13 activity influence 
VWF parameters and the bleeding phenotype of VWD. We there-




We included individuals from the nationwide cross-sectional 
Willebrand in the Netherlands (WiN) study. Individuals were in-
cluded in the WiN study if they had (1) a hemorrhagic diathesis or a 
positive family history for VWD, and (2) historically lowest VWF an-
tigen (VWF:Ag) and/or VWF activity ≤ 30 U/dL or factor VIII coagu-
lant activity (FVIII:C) ≤40 U/dL (for individuals with type 2N). Details 
of the study design have been reported elsewhere.5 Individuals 
were excluded if they had also been diagnosed with another inher-
ited bleeding disorder. For this project, we included only individuals 
from whom plasma was obtained at inclusion in the WiN study and 
excluded individuals who were pregnant (n = 4) or who had used 
desmopressin or clotting factor concentrates within 72 hours be-
fore blood sampling (n = 15). By excluding all individuals who had 
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received clotting factor concentrate within the past 72 hours be-
fore blood sampling, we eliminated potential effects of the small 
amounts of ADAMTS-13 present in plasma-derived clotting factor 
concentrates.8
Healthy controls were included in a study on the biological varia-
tion of hemostasis variables.9 From 40 healthy individuals who were 
of similar age and sex distribution as the WiN study population, 
blood was collected during 13 visits over a 1-year period. One ran-
dom sample per individual was used for this study.
Both studies were approved by the Medical Ethics Committees 
at all participating centers and written informed consent was ob-
tained from all participants.
2.2 | ADAMTS-13 activity
Blood was collected in vacuum tubes containing 0.105 M sodium 
citrate and centrifuged, and the platelet-poor plasma was stored 
in aliquots at −80°C. ADAMTS-13 activity was measured using a 
kinetic assay based on the fluorescence resonance energy transfer 
substrate VWF 73.10 In this assay, a fluorogenic peptide contain-
ing 73 amino acids of VWF that encompasses the cleavage site of 
VWF for ADAMTS-13 (Tyr1605-Met1606) was added to patient 
plasma. Fluorescence emitted by the cleaved substrate was then 
measured against a reference curve of serial dilutions of normal 
human plasma defined to have an ADAMTS-13 activity of 1 IU/mL 




Other laboratory measurements, including VWF:Ag, VWF an-
tibody activity (VWF:Ab), VWF to collagen binding (VWF:CB), 
FVIII:C, and VWF propeptide (VWFpp) were measured as previously 
described.5,11,12
VWF multimers were quantified by densitometry using 
ImageQuant TL, version 8.1 (GE Healthcare Life Sciences, Amersham 
Place, United Kingdom). For each individual, we calculated the VWF 
large-multimer index as described by de Jong et al,13 which is a 
modification of the method introduced by Tamura et al.14 Briefly, 
densitometry images were divided into the five smallest bands, 
intermediate (bands 6-10), and large (all other bands). The VWF 
large-multimer index was then calculated by dividing the area of the 
large and intermediate multimers over the total area, relative to the 
control sample from the same multimer blot. A VWF large-multimer 
index of 1 reflects a normal multimer pattern, whereas lower index 
values reflect an increasing relative deficiency of the intermediate 
and large VWF multimers.
The lifelong bleeding phenotype of the patients was determined 
using a self-administered condensed Tosetto bleeding score (BS) as 
previously described.5 In short, 12 bleeding symptoms were system-
atically evaluated on occurrence and severity, with scores per symp-
tom ranging from −1 or 0 to 4. Higher scores reflect more severe 
bleeding. The bleeding phenotype was additionally determined by 
patient-reported occurrence of bleeding requiring hemostatic treat-
ment in the year before inclusion and blood sampling in the WiN 
study.15
2.3.2 | Healthy controls
VWF:Ag, VWF ristocetin cofactor (VWF:RCo), VWF:CB, and FVIII:C 
were measured as previously described.9
2.4 | Definitions
We classified every individual with VWD according to current guide-
lines.4,16 Individuals with a VWF:Ab/VWF:Ag ratio >0.60 were clas-
sified as type 1 VWD, while those with a VWF:Ab/VWF:Ag ratio 
≤0.60 were classified as type 2A or 2B or 2M VWD. Type 2 subtypes 
were further defined as abnormal multimer pattern with normal 
ristocetin-induced platelet agglutination (RIPA) test (2A); abnormal 
multimer pattern with abnormal RIPA test (2B); normal multimer 
pattern (2M); FVIII:C/VWF:Ag ratio ≤0.60 and reduced VWF:FVIIIB 
(2N). Individuals were classified as type 3 VWD if they had both 
VWF:Ag and VWFpp <5 U/dL. Individuals with VWF mutations con-
sistently described in the literature as a certain VWD type were clas-
sified as such even if the laboratory phenotype suggested another 
VWD type.
This classification differs from previous publications from the 
WiN study. Notably, in this study we used a more stringent cutoff 
value for the VWF activity/antigen ratio (0.7 in previous publica-
tions) to distinguish type 1 and 2 VWD. Moreover, individuals had to 
have both VWFpp and VWF:Ag <5 U/dL (vs only VWF:Ag in previ-
ous publication) to be classified as having type 3 VWD.
Based on the causal VWF mutation, individuals with type 2A 
VWD were further divided into those with impaired multimerization 
and those with increased susceptibility to ADAMST-13–mediated 
cleavage.17
2.5 | Statistical analysis
ADAMTS-13 activity in healthy controls and patients with VWD 
was compared by independent t test. The association between 
ADAMTS-13 and continuous variables was examined using linear 
regression models. Differences in ADAMTS-13 activity between pa-
tients with different VWD types were assessed using linear regres-
sion models adjusting for age; type 2 subtypes were compared using 
the Kruskal-Wallis test and post hoc Mann-Whitney U test with 
Bonferroni correction. All analyses were performed using SPSS, ver-
sion 21 (IBM Corporation, Armonk, NY, USA).
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3  | RESULTS
3.1 | ADAMTS13 activity in individuals with VWD 
and healthy controls
Demographics of the 638 individuals with VWD and 36 controls are 
shown in Table 1. ADAMTS13 activity did not differ between indi-
viduals with VWD (mean, 109% ± 20.6%) and controls (mean, 110% 
± 19.7%), 95% confidence interval (CI) −8.3%-5.5% (Figure 1A).
In the individuals with VWD, ADAMTS-13 activity was nega-
tively associated with age and decreased by 2.1% per 10-year age 
increase (95% CI, 1.2-2.9). ADAMTS-13 activity was similar in men 
and women (mean difference, −0.58%; 95% CI, −3.9 to 2.7) and in 
blood group O versus non-O (mean difference, 0.91%; 95% CI, −2.4 
to 4.2). In a subgroup analysis of type 1 VWD, there was no differ-
ence in ADAMTS-13 activity between the 270 blood group O in-
dividuals and 120 blood group non-O individuals (mean difference, 
1.8%; 95% CI, −2.6 to 6.3); adjusting for age and sex had no impact 
on this analysis.
After adjusting for age, ADAMTS-13 activity was higher in indi-
viduals with type 3 VWD than in individuals with type 1 (mean dif-
ference, 11.8%; 95% CI, 2.9-20.8) or type 2 VWD (mean difference, 
16.1%; 95% CI, 7.1-25.1); individuals with type 1 VWD had higher 
ADAMTS-13 activity than individuals with type 2 VWD (mean dif-
ference, 4.7%; 95% CI, 1.4-8.0) (Figure 1B). ADAMTS-13 activity 
also differed between the type 2 subtypes (χ2 [3] = 13.2; P = .004); 
after Bonferroni correction, ADAMTS-13 activity differed only be-
tween types 2B and 2N (P = .02) and between types 2M and 2N 
(P = .02) with 2N individuals having higher ADAMTS-13 activity 
(Figure 1C).
3.2 | ADAMTS-13 activity and the laboratory 
phenotype of VWD
ADAMTS-13 activity was not associated with VWF:Ag, VWF:Ab, 
VWF:CB, or FVIII:C (Table 2). After adjusting for age, there was no as-
sociation between ADAMTS-13 activity and these VWF parameters.
ADAMTS-13 activity was associated with VWFpp (age-adjusted 
0.8% decrease per 10 U/dL VWFpp increase, 95% CI, 0.5-1.2); 
ADAMTS-13 activity was also associated with VWFpp in type 1 
VWD (1.0% decrease per 10 U/dL VWFpp increase, 95% CI, 0.3-1.4) 
(Table 2).
After exclusion of individuals with type 3 VWD (ie, individuals 
without VWF multimers), ADAMTS-13 activity was associated with 
the VWF large-multimer index (0.8% increase per 0.1 point increase 
in VWF large-multimer index, 95% CI, 0.2-1.3) (Table 2). ADAMTS-13 
activity was not associated with the VWF large-multimer index in 
individuals with type 1 VWD.
Type 2A VWD can be caused by mutations that lead to intra-
cellular multimerization defects or that increase the susceptibility 
of VWF for proteolysis by ADAMTS-13. To test if ADAMTS-13 
activity differs between these type 2A subgroups, we stratified 
individuals with type 2A into these two groups, based on the 
causal VWF mutation17 (list of mutations in Table S1). After ad-
justing for age, ADAMTS-13 activity did not differ between 46 
individuals with a mutation that causes increased proteolysis by 
ADAMTS-13 and 32 individuals with a mutation that impairs VWF 
multimerization rather than proteolysis (mean difference, −6.7%; 
95% CI, −14.9 to 1.4).
3.3 | ADAMTS-13 activity and bleeding
When investigating all participants in the WiN study, ADAMTS-13 
activity was not associated with the Tosetto BS, adjusting for age 
and sex (0.1 BS increase per 10% ADAMTS-13 activity increase; 95% 
CI, −0.2 to 0.3) (Figure 2A and Table 3). Similarly, ADAMTS-13 was 
not associated with the Tosetto BS in individuals with type 1 VWD 
(0.0 BS increase per 10% ADAMTS-13 activity increase, 95% CI, 
−0.3 to 0.3 after adjusting for age and sex). Adjusting additionally 
for VWF:Ab had no effect on the observed associations between 
ADAMTS-13 activity and the Tosetto BS (Table 3).
ADAMTS-13 activity was similar in individuals with VWD who had 
(n = 188) and individuals who had not had (n = 420) a bleeding episode 
requiring treatment during the year before inclusion in the WiN study 
TA B L E  1   Participant demographics
VWD patients Healthy controls P value
Number 638 36
Age, y 44 (29-57) 38 (25-53) .23
Females 398 (62.4) 24 (66.7) .61
VWF:Ag 29 (18-45) 103 (80-118) <.001
VWF activity a  22 (8-52) 121 (104-146) <.001
VWF:CB 22 (7-51) 163 (131-195) <.001
FVIII:C 51 (32-73) 98 (83-118) <.001
VWD type
1 393 61.6 NA





3 22 3.4% NA
Note: Categorical values are shown as n (%); continuous variables are 
shown as median (interquartile range). 
P values were calculated with χ2 test (categorical variables) or Mann-
Whitney U test (continuous variables).
Abbreviations: FVIII:C, factor VIII coagulant activity; NA, not applicable; 
VWD, von Willebrand disease; VWF, von Willebrand factor; VWF:Ab, 
von Willebrand factor antibody; VWF:Ag, von Willebrand factor 
antigen; VWF;CB, von Willebrand factor to collagen binding; VWF:RCo, 
von Willebrand factor ristocetin cofactor.
aVWF activity was measured with VWF:Ab (individuals with VWD) or 
VWF:RCo (controls). 
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(age- and sex-adjusted mean difference, 1.6%; 95% CI, −1.9 to 5.0) 
(Figure 2B and Table 4). Similarly, among patients with type 1 VWD, 
ADAMTS-13 did not differ between individuals with and without such 
a bleed (age- and sex-adjusted mean difference, 0.5%; 95% CI, −4.5 to 
5.4). Adjusting additionally for VWF:Ab had no impact on these results.
4  | DISCUSSION
We hypothesized that variations in ADAMTS-13 activity could affect 
VWF parameters and subsequently influence the bleeding pheno-
type in individuals with VWD. In this first-ever study on ADAMTS-13 
and bleeding, we found no such association.
To our knowledge, only three studies have thus far investi-
gated ADAMTS-13 in individuals with VWD. In 2001, Mannucci 
et al18 measured ADAMTS-13 activity in six individuals with type 1 
Vicenza, five with type 3, and four with type 2A VWD. They found 
that the ADAMTS-13 activity measured in these individuals was in 
the normal range but did not provide further data. They also found 
a negative association between ADAMTS-13 activity and VWF:Ag 
(Pearson r, −.40) and VWF:CB (r, −.42). Their analysis included not 
only healthy individuals but also pregnant women and individu-
als with cirrhosis, chronic renal insufficiency, acute inflammatory 
states, and surgery, with extremely high VWF levels that sometimes 
exceeded 1000 U/dL.18
In a subsequent study, Mannucci and colleagues6 compared 
ADAMTS-13 activity in 33 individuals with type 3 VWD and 33 
healthy controls matched for sex, age, and blood group. In their 
study, the individuals with type 3 had a mean ADAMTS-13 activ-
ity of 136%, which was 38% higher than in healthy controls. They 
also observed unchanged ADAMTS-13 activity after desmopressin 
infusion in three individuals with severe VWD, which was in con-
trast to the 10%-20% ADAMTS-13 decrease after desmopressin in-
fusion in 10 healthy volunteers in their study. Based on these results, 
they suggested that ADAMTS-13 levels are regulated by circulating 
VWF.6
In another study, Reiter et al7 measured ADAMTS-13 activity 
after desmopressin infusion in three individuals with type 1 VWD 
and 10 healthy volunteers. They observed an ~60% decrease in 
ADAMTS-13 activity in both groups, which returned to baseline val-
ues after a few hours.
Our observation that ADAMTS-13 activity was not associ-
ated with VWF levels contradicts the association reported by 
Mannucci et al; this may be explained by an effect of severe dis-
ease on ADAMTS13 and VWF levels, rather than a direct interac-
tion between the two proteins. In large population-based studies, 
ADAMTS-13 also was not associated with VWF.2,19 The only “phys-
iological” circumstances in which VWF and ADAMTS-13 activity 
are associated seem to be when VWF is absent (type 3 VWD, as 
observed by us and Mannucci et al6), or secretion of VWF follow-
ing desmopressin (as observed by Reiter et al7). This is supported 
by the association between ADAMTS-13 and VWF propeptide as a 
marker of VWF secretion in the absence of an association between 
ADAMTS-13 activity and VWF antigen or activity.
Individuals with type 2N VWD had higher ADAMTS-13 activ-
ity than individuals with other type 2 subtypes. In individuals with 
hemophilia A, ADAMTS-13 decreases after FVIII infusion.20 This 
suggests that differences in FVIII:C levels could explain the higher 
ADAMTS-13 activity in individuals with type 2N, but is contradicted 
by the absence of an association between ADAMTS-13 activity and 
F I G U R E  1   ADAMTS-13 activity in individuals with VWD and healthy controls A, ADAMTS-13 activity was similar in healthy controls and 
individuals with VWD (compared with independent t test). B, ADAMTS-13 activity was higher in individuals with type 3 than in type 1 or 2 
VWD (compared using linear regression adjusting for age). C, ADAMTS-13 activity was higher in individuals with type 2N than in type 2B 
or 2M VWD (compared using Kruskal-Wallis and Mann-Whitney U test with Bonferroni correction). NS, not significant; *P < .05; **P < .01; 
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FVIII:C in our study. Studies with more individuals with type 2N 
VWD are needed to confirm our finding and to explain the higher 
ADAMTS-13 activity in type 2N.
Interestingly, age was the most important parameter that was 
associated with ADAMTS-13 activity in the individuals with VWD. 
Age as a determinant of ADAMTS-13 in the general population is 
well established, having first been described by Kokame et al10,21 
and reproduced in large population-based studies.2
In our study, ADAMTS-13 activity was not associated with lifelong 
bleeding phenotype determined with the Tosetto BS and bleeding 
incidence during the year before blood draw. The absence of an asso-
ciation between ADAMTS-13 and bleeding may be explained by the 
properties of the VWF protein. The A2 domain of VWF, in which the 
Tyr1605-Met1606 cleavage site for ADAMTS-13 is located, needs 
to unfold before cleavage by ADAMTS-13 can occur.22,23 This un-
folding is dependent on stress exerted by the blood flow on VWF,24 
to which ultra-large VWF multimers are much more sensitive than 
smaller multimers.25 It is likely that the decreased susceptibility of 
smaller VWF multimers for cleavage by ADAMTS-13 rather than 
ADAMTS-13 quantity is the rate-limiting step for further cleavage.
TA B L E  2   ADAMTS-13 and VWF parameters
Total VWD cohort (n = 638) Type 1 VWD (n = 393)
B (95% CI)
Mean of VWF 
parameter B (95% CI)
Mean of VWF 
parameter
VWF:Ag Crude −0.7 (−1.5 to −0.0) 33 IU/dL −0.7 (−1.5 to 0.2) 38.3 IU/dL
Adjusted −0.3 (−1.0 to 0.5) −0.2 (−1.2 to 0.7)
VWF:Ab Crude −0.1 (−0.6 to 0.5) 34 IU/dL −0.5 (−1.1 to 0.2) 47.6 IU/dL
Adjusted 0.2 (−0.3 to 0.8) −0.2 (−0.8 to 0.5)
VWF:CB Crude −0.8 (−0.6 to 0.5) 32 IU/dL −0.5 (−1.2 to 0.2) 44.9 IU/dL
Adjusted 0.2 (−0.4 to 0.7) −0.2 (−0.9 to 0.5)
FVIII:C Crude −0.0 (−0.5 to 0.5) 56 IU/dL 0.1 (−0.5 to 0.8) 67 IU/dL
Adjusted 0.3 (−0.2 to 0.8) 0.5 (−0.2 to 1.1)
VWFpp Crude −1.0 (−1.3 to −0.6) 97 U/dL −1.0 (−1.5 to −0.4) 94 U/dL
Adjusted −0.8 (−1.2 to −0.5) −0.8 (−1.4 to −0.3)
VWF large-multimer 
index
Crude 0.8a  (0.2 to 1.3) 0.86 0.5b  (−1.2 to 2.1) 1.0
Adjusted 0.8a  (0.2 to 1.3) 0.6 b  (−1.1 to 2.2)
Note: Table shows the association of ADAMTS-13 with VWF parameters with and without adjusting for age. B: change in ADAMTS-13 activity (%) per 
10 U/dL increase of each VWF parameter or 0.1 VWF large multimer index increase. Significant associations are shown in italics.
Abbreviations: CI, confidence interval; FVIII:C, factor VIII coagulant activity; VWD, von Willebrand disease; VWF, von Willebrand factor; VWF:Ab, 
von Willebrand factor antibody; VWF:Ag, von Willebrand factor antigen; VWF;CB, von Willebrand factor to collagen binding; VWFpp, von 
Willebrand factor propeptide.
aAfter exclusion of type 3 VWD patients and failed densitometric analysis (n = 523). 
bn = 319. 
F I G U R E  2   ADAMTS-13 activity 
and bleeding in individuals with VWD. 
A, Association between ADAMTS-13 
activity and the Tosetto BS. The linear 
regression line is shown after adjusting 
for age and sex (−0.1 BS increase per 10% 
ADAMTS-13 activity increase, 95% CI 
−0.4 to 0.2). B, ADAMTS-13 activity in 
individuals with and without a bleeding 
episode requiring hemostatic treatment 
during a 1-year period. BS, bleeding 
score; NS, not significant. Lines depict 
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Our observation that ADAMTS-13 is not associated with bleed-
ing is in line with data from a recently published phase 1 trial for 
recombinant ADAMTS-13 in individuals with congenital thrombotic 
thrombocytopenic purpura. In this study, none of the 15 included 
individuals reported bleeding after regular infusions of recombinant 
ADAMTS-13.26
A number of limitations need to be mentioned. In this sub-
study, we used different classification criteria than in previous 
projects in the WiN study. While using the most contemporary 
criteria makes for a better extrapolation of our data, caution 
should be used when comparing our results with previous reports 
from the WiN study, especially those on the association between 
fibrinolysis and bleeding.27,28 We have previously shown that the 
requirement of VWF propeptide levels <5 U/dL in addition to low 
VWF antigen and activity levels improves the classification of 
type 3 VWD.11
Moreover, it can be argued that the bleeding phenotype is insuffi-
ciently measured with the Tosetto BS, which has inherent limitations. 
It is a cumulative score with a so-called ceiling effect, and it is influ-
enced by recall bias. However, we have addressed these issues by also 
determining the incidence of bleeding requiring hemostatic treatment 
during the year before inclusion in the WiN study. This bleeding inci-
dence, which we consider a better reflection of the current bleeding 
phenotype, also was not associated with ADAMTS-13 activity.
In conclusion, ADAMTS-13 activity was higher in individuals 
with type 3 VWD, but it had only minor associations with VWF 
parameters. ADAMTS-13 activity does not influence the bleeding 
phenotype in individuals with VWD.
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TA B L E  3   ADAMTS-13 and Tosetto BS
Total VWD cohort (n = 604) Type 1 VWD (n = 377)
B (95% CI) Mean Tosetto BS B (95% CI) Mean Tosetto BS
Tosetto BS Crude −0.1 (−0.4 to 0.2) 11.5 −0.1 (−0.5 to 0.2) 10.1
Model 1 0.0 (−0.2 to 0.3) 0.0 (−0.3 to 0.4)
Model 2 0.1 (−0.2 to 0.3) 0.0 (−0.3 to 0.4)
Note: Model 1, adjusted for age and sex; Model 2, adjusted for age, sex and VWF:Ab. B reflects change in Tosetto BS per 10% increase in 
ADAMTS-13 activity.
Abbreviations: BS, bleeding score; CI, confidence interval; VWD, von Willebrand disease; VWF:Ab, von Willebrand factor antibody.
Total VWD cohort 





ADAMTS-13 activity Crude 1.9 −1.7 to 5.4 1.1 −3.8 to 6.1
Model 1 1.6 −1.9 to 5.0 0.5 −4.5 to 5.4
Model 2 1.4 −2.1 to 4.9 0.5 −4.7 to 5.4
Note: Table shows the mean difference in ADAMTS-13 activity between individuals with VWD 
with and without a bleeding episode during the year before inclusion in the WiN study. A positive 
difference reflects a higher ADAMTS-13 activity in patients without a recent bleeding. Model 1, 
adjusted for age and sex; Model 2, adjusted for age, sex, and VWF:Ab.
Abbreviations: CI, confidence interval; VWD, von Willebrand disease; VWF:Ab, von Willebrand 
factor antibody; WiN, Willebrand in the Netherlands.
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